TORONTO, CA - 04/28/2016 (PRESS RELEASE JET)
Oravital Inc., the Toronto-based developer of the Oravital® System for the diagnosis and treatment of the oral infections that cause gum disease, bad breath and cavities, recently launched its BiofilmDNA™ salivary test.
This highly-sensitive DNA test detects the numbers and presence of a wide variety of oral pathogens, via a combination of samples taken from the patient’s saliva, tongue and gums.
According to practicing Toronto dentist and Oravital CEO Dr. James Hyland, “This advanced and accurate analysis provides the dentist with a detailed, whole-mouth picture of their patient’s oral health - which is very important because unless the whole mouth is tested and treated, reinfection occurs.
Oravital’s new BiofilmDNA™ test is a powerful complement to its BiofilmGS™ test, which uses site-specific Gram stain analysis to determine the exact type and location of oral infection. Both the BiofilmDNA™ and BiofilmGS™ tests are analyzed in Oravital’s on-site, state-of-the-art lab facility, with reports available in about a week. Used together, the two biofilm tests will help the dental clinician accurately identify the following:
“The Oravital® System controls 90% of gum disease, bad breath and cavities in just 4 weeks. It achieves this by effectively closing the diagnosis/treatment loop by not only identifying the exact cause and location of an oral infection, but also providing a regimen of antibiotic and antimicrobial rinses that are specifically prescribed for the patient’s personal diagnosis,” adds Dr. Hyland.
The Oravital® System, is very comprehensive and consists of the following five steps:
About Oravital Inc.
Oravital Inc. was established in the fall of 2007 in Toronto, Canada. The company licenses proprietary technology called the Oravital® System to certified dental clinics throughout North America for the most advanced, effective and painless diagnosis and treatment of oral infections available today.
With recent studies linking oral infections with systemic conditions such as heart disease and diabetes, periodontal disease is now considered a medical condition that dental professionals should treat. What’s more, given that 75% of the population continues to have signs of gum disease in spite of our best efforts, diagnosis and predictable treatment of this infection has become extremely important. Oravital's system controls 90% of gum disease, bad breath and cavities in just 4 weeks.
Oravital’s proprietary protocol of inexpensive biofilm testing and the use of prescribed antibiotic and antimicrobial rinses dramatically halt the progress of periodontal disease and breath odor. Bleeding is reduced by 87%, and pocket depths shrink by 76 to 84% within a few weeks. Oravital® proprietary rinses treat the entire oral complex and are non-systemic (not pills). The Oravital® System is the only system to predictably treat the oral-systemic link.
The science of Oravital® evolved from 15 years of ground-breaking research and successful clinical treatment by Anne Bosy, RDH, MEd, MSc, who was the co-founder of Toronto's Fresh Breath Clinic. Dr. Walter Loesche, who was a respected authority on periodontal disease treatment at the University of Michigan, validated the effectiveness of the antibiotic therapy developed by Anne Bosy in the “Southward Study Treatment of Malodour Using an Antibiotic Rinse”. (Published in General Dentistry, July 2013)
Oravital Inc. also provides a comprehensive, dynamic and scientifically-grounded training program to its certified clinics. Oravital® certified dental professionals are authorized experts in providing Oravital® diagnostic analysis, individualized treatment, and dedicated long-term support. For more information, visit www.oravital.com or call 1-800-909-6468.
|person_outline||Full Name:||Michael Ventriello|
|business_center||Company:||Ventriello Communications, LLC|
|mail_outline||Email: Send Email|